Peer Review History
Original SubmissionOctober 24, 2023 |
---|
PONE-D-23-34561Phenolic compounds of Theobroma cacao L. showed inhibitory effects on dengue RdRp protease enzyme: Findings from in-silico docking, MD simulation, MMGBSA and DFT calculationsPLOS ONE Dear Dr. Islam, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jan 21 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Erman Salih Istifli, PhD Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Thank you for stating the following in the Acknowledgments Section of your manuscript: "This study was supported by the Lembaga Koko Malaysia (University Reference Number: RDU 210710) to Saiful Nizam Tajuddin." We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: "The author(s) received no specific funding for this work" Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: N/A Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Recommendation: Major revision Comments: - In the molecular docking section explain why PDB ID: 6IZZ was used to perform docking studies. Describe the mutations, missing regions and active or inactive states of the receptors. - The binding interactions between Catechin and RdRp protease should be visualized in 2D and 3D images. - The conclusion part should be more informative. - The word in vivo and in vitro should be written in Italic form throughout the manuscript. - The word IC50 should be corrected to IC50. - Many paragraphs need to be justified. - In the introduction section, the authors need to discuss some recent reports about molecular docking and its role in the interactions of potential candidates with their target. You can depend on the following articles - https://doi.org/10.3390/molecules27227719 - https://doi.org/10.3390/molecules27185859 - https://doi.org/10.3390/molecules27155047 - The quality of the images of MD simulation are very low and should be improved. - The manuscript should be written in standard English - Writing of the manuscript for language and grammar needs to be thoroughly checked. Reviewer #2: Dear Authors, First: I have reviewed the section of your manuscript concerning the Molecular Dynamic (MD) simulations and would like to discuss the interpretation of the RMSD (Root Mean Square Deviation) and RMSF (Root Mean Square Fluctuation) values in relation to the stability of the (+)-Catechin-protein complex. In your manuscript, you mention that the (+)-Catechin-protein complex exhibited stability throughout the 100 ns MD simulation period. However, I observed that the RMSD value for the complex increased significantly, reaching up to 25.5 Å, and the average RMSD was reported as 18.0 Å【17†source】. Typically, a lower RMSD value during a simulation indicates a stable protein-ligand complex, while a higher RMSD value suggests less stability. Furthermore, the RMSF values, which reflect the flexibility and mobility of amino acid residues during the simulation, also showed considerable variation, with the average RMSF observed for RdRp following binding of (+)-Catechin being 10.0 Å【18†source】. Higher RMSF values typically indicate greater flexibility and potentially less stability in specific regions of the protein. Given these observations, it seems that there is a contradiction in stating that the complex remains stable while the RMSD and RMSF values suggest significant fluctuations and changes in the structure. It would be beneficial for the manuscript if you could clarify the following points: 1. Interpretation of RMSD Values: How do you reconcile the relatively high RMSD values with the conclusion that the complex is stable? Is there a specific criterion or threshold you are using to define stability in this context? 2. RMSF Insights: Could you provide more insights into the high RMSF values observed? Are these fluctuations concentrated in specific regions of the protein, and do they affect the overall stability of the complex? 3. Impact on Binding Efficacy: How do these fluctuations influence the binding efficacy and potential inhibitory action of (+)-Catechin on the RdRp protease? Your clarification on these points would greatly enhance the understanding of the MD simulation results and their implications for the stability and efficacy of the (+)-Catechin-protein complex as a potential DENV inhibitor. Second: I have carefully reviewed your manuscript, particularly the Molecular Dynamic (MD) simulations section, focusing on the RMSF (Root Mean Square Fluctuation) values of the (+)-Catechin-protein complex. One key aspect that appears to be missing in your analysis is the comparison of these RMSF values with the RMSF of the apo protein (the unbound state of the protein). In your study, you report the RMSF values for the (+)-Catechin-protein complex, highlighting the flexibility and mobility of amino acid residues during the simulation. These values provide essential insights into the stability and conformational dynamics of the protein-ligand complex【18†source】. However, for a comprehensive understanding of how the binding of (+)-Catechin affects the protein, it would be beneficial to compare these results with the RMSF of the protein in its unbound state. Such a comparison can offer valuable information on the following: 1. Effect of Ligand Binding on Protein Dynamics**: Comparing the RMSF values of the apo protein with the complex can reveal if and how the binding of (+)-Catechin alters the dynamic behavior of the protein. This can be particularly informative for understanding any conformational changes or stabilization effects induced by ligand binding. 2.Regions of Increased or Decreased Flexibility**: By contrasting the RMSF profiles of the apo and bound states, you can identify specific regions in the protein that become more or less flexible upon ligand binding. This can provide insights into the mechanism of inhibition and the structural basis of the protein's functional modulation. 3. Benchmark for Stability Analysis**: Comparing the RMSF values of the apo and bound states can serve as a benchmark to assess the relative stability imparted by ligand binding. This comparison could strengthen your conclusions about the stability and efficacy of the (+)-Catechin-protein complex as a potential inhibitor. I believe that incorporating this comparative analysis would greatly enhance the depth and significance of your MD simulation results, offering a more nuanced understanding of the interaction dynamics between (+)-Catechin and the RdRp protease. Third: Regarding the section "3.5. Density Function Theory (DFT) Calculations" in your manuscript, I would like to offer a brief comment for improvement. While the results in Table 1 provide valuable data on the electronic properties of (+)-Catechin, there appears to be a missed opportunity in not further interpreting these results to deduce the nature of this compound in terms of its reactivity and interaction mechanism. Your analysis effectively identifies the HOMO and LUMO energy levels, and the energy gap, but stops short of extrapolating how these properties translate into the compound's behavior as an electron donor or acceptor. Such an interpretation is crucial for understanding the molecular basis of its potential inhibitory action on the RdRp protease. This additional step of analysis could significantly strengthen your DFT section, providing deeper insights into the electronic characteristics and reactivity of (+)-Catechin, and how these properties contribute to its function as a potential inhibitor. It would be beneficial to readers and the field if this aspect could be explored and discussed. fourth: I have reviewed your manuscript and would like to recommend the inclusion of some recent and relevant references that could significantly enhance the depth and context of your work. These references provide insights and data that align closely with your study's focus and could offer additional perspectives or comparative data to strengthen your arguments. 1. [Molecules: DOI 10.3390/molecules27196320] 2. Reference on Molecular Docking and Simulation Techniques: [Crystals: DOI 10.3390/cryst13071086](https://doi.org/10.3390/cryst13071086) 3. Reference on Density Functional Theory (DFT) Analysis: [Crystals: DOI 10.3390/cryst13071020] This article covers the latest developments in DFT calculations, potentially providing a broader context or newer techniques that could be applied to your DFT analysis. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
Revision 1 |
Phenolic Compounds of Theobroma cacao L. show potential against dengue RdRp Protease enzyme inhibition by In-silico Docking, DFT study, MD simulation and MMGBSA calculation PONE-D-23-34561R1 Dear Dr. Islam, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Erman Salih Istifli, PhD Academic Editor PLOS ONE Additional Editor Comments (optional): I have assessed the manuscript and despite the conflicting reviewers recommendations, I feel this study is thorough and the manuscript is suitable for publication. The study by Islam et al. employed sufficient methodology required for a structure-based drug design study. Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: No ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: N/A Reviewer #2: I Don't Know ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors have refuted most of my comments and therefore I recommend accepting the manuscript in the current form Reviewer #2: Title: Disapproval of Manuscript Review Response for the Study on Phenolic Compounds of Theobroma cacao L. in "PLOS ONE" Dear Editors of PLOS ONE, I am writing to express my dissatisfaction with the responses provided to comments raised during the review of the manuscript titled "Phenolic Compounds of Theobroma cacao L. show potential against dengue RdRp Protease enzyme inhibition by In-silico Docking, DFT study, MD simulation and MMGBSA calculation." Despite having carefully reviewed the study, I found the responses to the comments to be unsatisfactory. The explanations provided were not sufficiently scientific, and the details were not adequately addressed. I believe that the manuscript, in its current state, is not suitable for publication. The lack of precision and scientific rigor in the explanations raises concerns about the credibility and reliability of the presented findings. Therefore, I must express my opinion that, from my perspective, the manuscript is not suitable for publication in its current form and should be rejected. I hope that my concerns are taken into consideration during the evaluation process. Thank you for your attention to this matter. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** |
Formally Accepted |
PONE-D-23-34561R1 PLOS ONE Dear Dr. Islam, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Assoc. Prof. Dr. Erman Salih Istifli Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .